reason report
eylea hang libtayo come target-price
strong quarter top-line bottom line beat consensu
despit covid effect late y/i declin us eylea
sale april significantli better street anticip
declin in-offic visit eylea certainli
wood yet re-open process ophthalmolog
practic like slow case latest inform
suggest likelihood less sever impact least
april compani indic procedur volum product
shipment start improv last two week april
first two week follow pattern impair volum seen late
march manag suggest beovu launch basic hit
wall middl pandem crisi expect result
neglig share novarti highli promot product middl
crisi next imposs novarti explain away
isol sever advers event regeneron like benefit
extens safeti experi strong relationship
program track clinic trial initi next month manag
expect result hospit patient first like
month follow result prophylact early-stag set
compani advanc two differ antibodi cocktail one
base tradit mouse-bas antibodi screen
recent human convalesc plasma antibodi screen
manag indic antibodi manufactur
would reach hundr thousand dose per month summer
potenti scale outsourc manufactur
capac suppli potenti make meaning impact
diseas given typic singl dose treatment econom
antibodi program explicitli discuss
call manag expect least cover overhead cost
price manag also present initi guidanc
call follow closur antibodi financi
statement restructur format new guidanc remain larg
unchang focus transpar present expens
much appreci non-gaap opex guidanc lower
consensu reflect cost save associ antibodi
restructur make clear compani improv profit
despit temporari pandem disrupt optimist
regeneron top-line growth margin improv like
continu dupix libtayo collabor continu
compani inform svb leerink llc research
revenu mm dilut ep non-gaap
averag price-to-earnings p/ dcf
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
improv profit look ahead regeneron libtayo
seem like increas import given posit data basal cell
carcinoma recent strong interim result front
line non-smal cell lung cancer nsclc studi base compani
surprisingli posit result commentari continu strong
trend dupix well grow revenu potenti libtayo
rais revenu forecast
later year increas earn forecast year
later year new revenu forecast
consensu beyond ep estim
consensu year target price increas
reiter outperform rate regn stock
basal cell carcinoma data less impress cscc
get approv briefli earn press releas yesterday
morn regeneron announc pivot trial data libtayo basal cell
carcinoma durabl efficaci look posit
year patient studi show rel low overal
respons rate orr compar cutan squamou cell
carcinoma cscc nsclc believ data
suffici approv libtayo like prefer treatment
hedgehog pathway inhibitor intoler patient local advanc
metastat despit disrupt mani regeneron
on-going clinic program manag indic bispecif
program remain activ even though timelin seem like
delay sever month least expect updat phase
data bispecif american societi clinic
oncolog week pivot studi continu
enrol anticip complet enrol
fasinumab ngf ab phase result osteoarthr pain also expect
month though manag caution dose select
efficacy/safeti balanc dupix ad approv expect later
month delay addit regeneron plan file fda
submiss garetosmab fibrodysplasia ossifican progressiva
well evinacumab homozyg famili hypercholesterolemia
second half year
increas revenu forecast reflect resili eylea sale
addit indic libtayo price target reiter
op base latest eylea perform libtayo clinic
progress nsclc increas revenu forecast
regeneron revenu
forecast chang mainli driven higher us eylea forecast
higher libtayo forecast
declin increas new libtayo
forecast includ newli ad indic po
nsclc po increas new revenu forecast
in-lin consensu higher
oper expens estim decreas
driven lower sg estim inclus
oper expenses/incom up-front mileston payment
updat pro forma ep estim increas
materi higher consensu
futur year base today chang reiter
outperform rate regn stock modestli increas price
target
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani grow strongli base success first truli
novel medicin dupix allerg diseas first product eylea continu surpris
investor taken grown market intraocular vegf vascular
endotheli growth factor antibodi treatment eylea contribut global sale
trump categori pioneer roch lucenti well cheaper altern
compound bevacizumab eylea also seem easili absorb launch novarti
beovu show sign continu growth multipl indic remain posit
eylea expect continu grow excit aspect compani
next wave innov antibodi notabl dupix approv adult
atop dermat asthma like receiv label expans multipl allerg diseas
indic expect dupix dupilumab gener revenu
peak signific upsid indic longer term regeneron
wholli own antibodi could contribut meaning revenu earn growth
period current compani invest mode result
earn cash flow convers revenu lag peer industri anticip
cash flow true earn improv period profit antibodi
collabor sanofi begin accumul
revenu consensu unexpectedli resili eylea sale
total revenu reach y/i beat consensu
forecast
global eylea growth remain strong beat consensu covid-cauti forecast
global eylea net sale consensu
higher forecast manag indic us eylea sale
declin second half march second week april sharp
rebound past week manag also point us eylea sale april
decreas y/i compar increas y/i y/i declin us eylea sale
april significantli better street anticip declin in-offic visit
eylea certainli wood yet re-open process ophthalmolog
practic like prolong latest inform suggest likelihood less sever
impact least april manag suggest beovu launch basic hit
wall amid pandem crisi believ eylea reliabl effect vegf agent
like solidifi lead role long run
dupix beat consensu grow sequenti yoy dupix sale
reach consensu lower estim manag
indic dupix sale impact disrupt new patient
start slow april primarili due dermatolog practic manag estim limit
volum impact asthma indic
us libtayo sale higher consensu overal uptak remain slow global
libtayo sale beat consensu materi miss estim
sequenti growth almost flat suggest penetr cscc like near peak
manag indic libtayo stabil penetr potenti
approv later year earli next year anticip libtayo gain addit
traction howev upsid like limit
praluent sale higher consensu kevzara sale miss
consensu sanofi antibodi profit increas total collabor revenu
regeneron partnership sanofi bayer new account
structur antibodi collabor reimburs net expens
estim consensu praluent exclud antibodi collabor
antibodi profit expect grow faster pace move forward
non-gaap ep consensu driven higher revenu expens
consensu
regeneron report oper expens slightli lower consensu
estim regeneron also report lower tax rate compar consensu
estim oper margin increas improv
prior quarter dilut share count higher consensu
estim combin item help deriv pro forma ep
consensu higher estim
manag also present initi guidanc call follow closur
antibodi restructur format new guidanc remain larg unchang
focus expens non-gaap opex guidanc lower consensu reflect
cost save associ antibodi restructur non-gaap expens
higher estim bracket consensu non-gaap
sg expens estim consensu
non-gaap cog bracket estim lower consensu
manag guid non-gaap tax rate bracket estim
lower consensu manag slightli reduc capital-expenditure
guidanc still materi higher estim
consensu
antibodi cocktail data come august libtayo file
manag provid updat antibodi cocktail program plan
regeneron start clinic studi june three set prophylact early-stag
hospit expect result within month end summer year
manag indic antibodi manufactur would reach hundr
thousand dose per month summer potenti scale outsourc
regeneron announc mix pivot data libtayo basal cell carcinoma
durabl efficaci look posit year patient studi show
rel low overal respons rate orr compar cscc nsclc
believ data shall offer pass approv libtayo like prefer treatment
hedgehog pathway inhibitor intoler patient local advanc metastat despit
disrupt mani regeneron on-going clinic program manag
indic bispecif program remain effect expect updat phase data
bispecif week pivot studi continu enrol
anticip complet enrol fasinumab phase result also expect
month though manag caution dose select efficacy/safeti balanc
dupix ad approv expect later month delay addit regeneron
plan file fda submiss garetosmab fibrodysplasia ossifican progressiva well
evinacumab homozyg famili hypercholesterolemia second half year
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani price
sale multipl larg cap high growth compani discount cash flow dcf use
averag larg cap larg molecul therapeut compani
rhhbi nv sni earn multipl ep appli current
ep estim give valu use slow growth revenu
multipl similar compani nv sni azn novo rhhbi
consensu sale appli revenu estim
give valu lastli dcf valuat given wacc termin cash
flow growth rate give present valu averag three method
current price target
risk view outlook valuat regeneron includ major chang price
reimburs coverag label competit posit eylea compani main
product today risk includ commerci develop disappoint compani
next partner program launch dupix kevzara well continu weak
demand price pressur compani cholesterol treatment praluent lastli
compani convert rel littl revenu cash flow today histori return
cash investor ultim may undermin valu stock investor
willing continu
sale
collabor
share count period dilut mm
guidanc
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
fasinumab libtayo nsclc
sec gov compani websit present svbl analysi
follow safeti
bla file
us approv
potenti bla file
phase result
top-line pivot data
phase data
phase data
interim result
studi
phase data
phase data
phase data
phase data
phase data
phase data
data
phase data
phase data
phase data
fda decis pediatr ad patient
phase result follow safeti
sbla file
us regulatori file
potenti bla file
full data expect
updat phase data potenti
combo immunotherapi present
futur medic confer
manag report phase data futur
svb leerink llc equiti research compani file
brand
type event
event trial detail
date known
up/down
expect
million
svb leerink llc partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
svb leerink llc research compani file
analysi stock price svb leerink target regeneron
method high growth larg cap biopharma ep multipl forma
ep rhhbi nv sni
svb leerink forma ep estim
impli price ep
equiti
number period
method larg cap biopharma forward multipl appli expect
revenu
larg cap high growth biopharma price/sal multipl
svb leerink revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
svb leerink llc research compani file factset
